Competition in the radioisotopes market: evaluation and analysis of drivers which affect mo-99 market share
| dc.contributor.author | Moremi, Lesedi Maiphepi | |
| dc.contributor.supervisor | Kapp, Erika | |
| dc.date.accessioned | 2024-11-04T08:18:54Z | |
| dc.date.available | 2024-11-04T08:18:54Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | This research aims to evaluate competition in the radioisotopes market and to analyze drivers that affect the market share of radioisotopes, particularly Molybdenum 99 (Mo-99), the most widely used radioisotope in medical procedures. Radioisotopes are safe radioactive substances used globally primarily for diagnosing and treating medical conditions (e.g. oncology, cardiology, thyroid disorders, and neurology). These radioactive substances include, but are not limited to Mo-99, Iodine-131 (I-131), Lutetium 177 non-carrier-added (Lu-177 n.c.a.) & Fluorine-18 (F-18)), that are used as Active Pharmaceutical Ingredients (APIs) for the manufacture of radiopharmaceuticals. The most prevalent diagnostic radioisotope among these fission isotopes, Mo-99, which is used to create Technetium-99m(Tc-99m), is estimated to be utilized in roughly 85% of nuclear medicine diagnostic scans carried out globally (National Academies Press, 2009). | |
| dc.identifier.uri | https://hdl.handle.net/10566/17101 | |
| dc.language.iso | en | |
| dc.publisher | Universty of the Western Cape | |
| dc.subject | Radioisotopes | |
| dc.subject | Molybdenum-99 (Mo-99) | |
| dc.subject | Technetium | |
| dc.subject | Market share | |
| dc.subject | Nuclear Medicine | |
| dc.title | Competition in the radioisotopes market: evaluation and analysis of drivers which affect mo-99 market share | |
| dc.type | Thesis |